- NCIt
- C39750
Loading cancer entity…
Loading cancer entity…
Clinical trials
303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (64)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05091866 | Natural Progesterone for the Treatment of Recurrent Glioblastoma | terminated | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06649851 | G-CSF After Chemo-radiation in Patients With Glioblastoma | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04396860 | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | completed | Phase 2 / Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04817254 | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06419946 | Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | recruiting | Phase 3 | 200 | Vastra Gotaland RegionOTHER_GOV | 4 | Apr 13, 2026 | clinicaltrials |
| NCT07134842 | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.(WinGlio-ipi) | recruiting | Phase 1 | 16 | University College, LondonOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | recruiting | Phase 2 | 36 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05789394 | Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | recruiting | — | 120 | Baptist Health South FloridaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04216329 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07347210 | Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma(MATVAC-1) | not yet recruiting | Phase 2 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05465954 | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 54 | Mayo ClinicOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | terminated | Phase 2 | 30 | Shuttle Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04945148 | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide(OPTIMUM) | recruiting | Phase 2 | 640 | Hopital FochOTHER | 2 | Nov 21, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT03746080 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | completed | Phase 2 | 21 | Lawrence D RechtOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06455605 | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | recruiting | Phase 1 | 46 | Darell BignerOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05734560 | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | recruiting | Phase 1 / Phase 2 | 50 | Darell BignerOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT01931098 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03137888 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05929495 | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | recruiting | Phase 2 | 25 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05375318 | BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels(BIOhabitats) | completed | — | 50 | Juan M Garcia-GomezOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | recruiting | Phase 1 | 66 | Orbus Therapeutics, Inc.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT03452930 | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | completed | Phase 1 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05759195 | Biomolecular Analysis for Predicting Response to Regorafenib(RegoRec) | completed | N/A | 53 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05941234 | Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma(IPerGlioGEM) | recruiting | N/A | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT01903330 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | unknown | Phase 2 | 84 | Epitopoietic Research CorporationINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | terminated | Phase 2 | 90 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | terminated | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials